SEC Form 3
FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 12/03/2020 | 3. Issuer Name and Ticker or Trading Symbol Clovis Oncology, Inc. [ CLVS ] | |||||||||||||
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) 12/07/2020 | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 1,976(1) | I | By wife |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (right to buy) | (2) | 09/01/2027 | Common Stock | 6,000 | 76.65 | I | By wife |
Stock Option (right to buy) | (3) | 01/31/2030 | Common Stock | 500 | 8.29 | I | By wife |
Restricted Stock Units | (4) | 03/01/2028 | Common Stock | 93 | (7) | I | By wife |
Restricted Stock Units | (5) | 02/01/2029 | Common Stock | 1,250 | (7) | I | By wife |
Restricted Stock Units | (6) | 01/31/2030 | Common Stock | 2,900 | (7) | I | By wife |
Explanation of Responses: |
1. These shares were omitted from the reporting person's original Form 3, and also were omitted from two Forms 4 filed by the reporting person after his original Form 3 was filed. |
2. On September 5, 2017, the reporting person was granted 6,000 options. The option vested as to 25% of the shares on September 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date. These shares were omitted from the reporting person's original Form 3. |
3. On January 31, 2020, the reporting person was granted 500 options. The option vested as to 25% of the shares on January 31, 2021, and the remainder vests in substantially equal installments over the 36 months immediately following such date. These shares were omitted from the reporting person's original Form 3. |
4. On March 1, 2018, the reporting person was granted 297 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. These shares were omitted from the reporting person's original Form 3. |
5. On February 1, 2019, the reporting person was granted 2,500 Restricted Stock Units. 50% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests on February 1, 2021. These shares were omitted from the reporting person's original Form 3. |
6. On January 31, 2020, the reporting person was granted 2,900 Restricted Stock Units. 25% of such Restricted Stock Units vests on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. These shares were omitted from the reporting person's original Form 3. |
7. Each Restricted Stock Unit represents the right to receive one share of Common Stock. |
Remarks: |
Senior Vice President and Chief Scientific Officer |
/s/ Thomas C. Harding | 02/19/2021 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |